xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Rockville, MD , Jan. 09, 2018 -- Drug discovery services have undergone a drastic change with the advancements in modern molecular biology methods and advanced knowledge of human genome. Drug discovery is becoming more hypothesis-driven target-based approach. Pharmaceutical companies and regulatory bodies are contributing to the drug discovery. Major pharmaceutical companies are also focusing on developing the team of excellent scientists working in many therapeutic fields and technologies. In the recent years, there has been an increase in a number of approvals for first-in-class drugs, this reflects the impact of advanced drug discovery technologies, and approaches. Drug discovery service providers are also focusing on sequencing of the human genome in order to open the way to genomics-based methods in drug discovery. Innovation currently seen in the drug discovery methods is based on more information about targets, disease phenotypes, and compounds.
Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=375
The report compiled by Fact.MR expects the global drug discovery services market is to witness robust growth, registering CAGR of 8.9% during 2017-2026. By the end of 2026, the global drug discovery services market is projected to reach US$ 16,800.1 million revenue. Increasing prevalence of chronic diseases and new diseases is driving the drug discovery services. Also, new technologies supporting drug discovery methods and techniques are evolving at a significant phase. Following are insight on how the global drug discovery services market will perform in the near future.
6 Key Insights on Global Drug Discovery Services Market
1- North America is likely to remain dominant in the global drug discovery services market throughout the forecast period 2017-2026. Presence of leading pharmaceutical companies in the region is one of the factors driving the growth of drug discovery services in North America.
2- Asia Pacific Excluding Japan (APEJ) is also anticipated to witness significant growth during 2017-2026. India and China are slowly becoming preferred locations for drug discovery outsourcing due to the technological capabilities developed. Fewer regulations and low manufacturing costs are also fueling the growth in APEJ region.
3- Hit-To-Lead identification is likely to be the most preferred process in the global drug discovery services market. By the end of 2026, hit-to-lead identification is projected to reach nearly US$ 7,000 million revenue.
4- By drug discovery service type, medicinal chemistry is likely to witness the significant growth. Towards the end of 2026, medicinal chemistry is projected to surpass US$ 6,000 million revenue.
Browse Full Report with TOC- https://www.factmr.com/report/375/drug-discovery-services-market
5- Small molecules are anticipated to be the largest drug type in the global drug discovery service market. Small molecules are projected to create an incremental opportunity of more than US$ 5,800 million between 2017 and 2026.
6- On the basis of therapeutic area, highest growth is expected to be seen in oncology. Oncology is projected to reach nearly US$ 7,000 million revenue towards the end of 2026.
The report offers a profile of some prominent players in the global drug discovery services market, which will stay active through 2026. The leading companies are Thermo Fisher Scientific, Inc., Merck Millipore, GE Healthcare, Albany Molecular Research, Inc. (AMRI), Charles River Laboratories International, Evotec, Pharmaceutical Product Development, LLC. (Ppd), Covance, Jubilant Biosys, Genscript Biotech Corporation, Aurigene Discovery Technologies, Wuxi Apptec, and Syngene.
Request For Discount - https://www.factmr.com/connectus/sample?flag=D&rep_id=375
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Mr. Rohit Bhisey Fact.MR 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Email: [email protected] Web: https://www.factmr.com/
